Odalasvir
Odalasvir
Odalasvir (pronounced: oh-dah-las-veer) is an experimental antiviral drug used in the research for treatment of Hepatitis C. It is a second-generation NS5A inhibitor that has shown high potency in vitro against all major Hepatitis C genotypes.
Etymology
The name "Odalasvir" is derived from the chemical structure of the drug. The "Oda" part of the name refers to the oxime moiety in the chemical structure, while "lasvir" is a common suffix for antiviral drugs, particularly those targeting the NS5A protein.
Mechanism of Action
Odalasvir works by inhibiting the NS5A protein, which is essential for the replication of the Hepatitis C virus. By blocking this protein, Odalasvir prevents the virus from multiplying and spreading to new cells.
Clinical Trials
Odalasvir has been studied in several clinical trials, often in combination with other antiviral drugs. In a Phase II trial, a combination of Odalasvir and Sofosbuvir demonstrated high rates of sustained virologic response in patients with Hepatitis C.
Related Terms
External links
- Medical encyclopedia article on Odalasvir
- Wikipedia's article - Odalasvir
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski